本帖最后由 老马 于 2012-1-13 21:20 编辑 . [9 c+ L: ~ G. ]* E3 W
* H5 z* K1 q. _5 c4 |爱必妥和阿瓦斯丁的比较
! E7 f& ]# C" w5 Q# T
{1 N2 q( {; ~; x2 \
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 P" @7 Z! |4 c' h" m' v" l4 A
0 R) Z2 o8 }0 Y) X% X; m
, O' O& d* `+ p6 ~+ M* U9 _* Y( Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: n% F! Q9 x. f) ~4 V" q+ k
==================================================; \7 M; E7 g @
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( l4 g, f( h! e- S' g
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# K6 p: K# c) ]9 Z# q+ @! AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; U+ }7 h u6 J' o! c4 }
|